Develops antibody drug candidates for people with immune-mediated diseases, including kidney and systemic autoimmune disorders.
10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet…View ↗
Our lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells.…View ↗
CLYM116View ↗
No revenue reported yet.
10-K for FY2025, filed Mar 5, 2026
Therapeutic focus
The focus moved from chemical drug candidates for neuronal excitability disorders, such as epilepsy and pain, to antibody candidates for immune-mediated diseases, including kidney and systemic autoimmune disorders.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet…View ↗
Our lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells.…View ↗
CLYM116View ↗
Competes with Amgen, IASO Biotherapeutics, AbbVie, Cullinan Therapeutics, Zenas BioPharma, L. Hoffmann-La Roche, Merck &, Novartis, Bristol Myers Squibb, Cabaletta Bio, Kyverna Therapeutics, Nkarta, Otsuka Pharmaceutical, Jade Biosciences, Vertex Pharmaceuticals, Vera Therapeutics, Biogen, Takeda Pharmaceutical, Biohaven, and argenx
10-K for FY2025, filed Mar 5, 2026The competitive landscape for budoprutug includes multiple companies developing biologics and other modalities targeting CD19 for…View ↗
Loading...